News >

Patient-Reported Outcomes With Stem Cell Transplant Signal Progress in Myeloma

Caroline Seymour
Published: Wednesday, Aug 08, 2018

Noa Biran, MD

Noa Biran, MD
Preliminary pilot data presented at the 2018 ASCO Annual Meeting suggest that autologous stem cell transplant (ASCT) does not impair short-term cognition, function, or symptoms of patients with newly diagnosed multiple myeloma, explained lead study author Noa Biran, MD.

Patient-reported outcomes focused on cognition, symptom extremity, and financial toxicity following ASCT. Patients were examined prior to and 6 months following treatment.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication